The hematopoietic microenvironment is a complex structure in which stem 
Introduction
Recent studies demonstrate that extracellular matrix (ECM)' molecules play a fundamental role in blood cell proliferation and/or differentiation. These molecules function to retain (or localize) hematopoietic cells within the marrow (1, 2) , to augSend correspondence to Michael W. Long Receivedfor publication JO February 1992 and in revisedform 6 March 1992.
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Abbreviations used in this paper: BFU-E, erythroid burst-forming progenitor cells; BFU-MK, burst-forming megakaryocyte progenitor cells; CFC, colony-forming cells; CFU-GM, granulocyte-macrophage progenitor cells; CSF, colony-stimulating factor; ECM, extracellular matrix; EPO, erythropoietin; Fn, fibronectin; GEMM, pluripotent (mixed cellularity) progenitor cells which give rise to granulocyte, erythrocyte, macrophage, and megakaryocyte containing colonies; GM, granulocyte / / macrophage; HPP-CFC, high proliferative potential colony-forming cells; IL-3, interleukin-3; TSP, thrombospondin. ment and/or stimulate hematopoietic cell development (3, 4) , and to localize hematopoietic growth factors (5, 6) . However, the complexity of the matrix itself is a major obstacle to the functional analysis of ECM in hematopoiesis. While the extracellular matrix is comprised of various collagens, proteoglycans, and glycoproteins, its composition varies throughout the body (7) . Bone marrow ECM contains fibronectin (Fn), thrombospondin (TSP), types III and IV collagen (8) , all of which play a role in hematopoiesis, as do other marrow-specific components such as hemonectin (9) and tissue-specific proteoglycans (10) . Indeed, the glycosaminoglycan side chains ofproteoglycans, such as heparan sulfate, bind hematopoietic growth factors (5), suggesting that ECM growth factor complexes are important for blood cell development.
Methods
Human bone marrow cells were obtained following informed consent and separated by three-color flow cytometry based on the expression of CD34, HLA-DR, and CD 15 antigenic determinants as described elsewhere (11) . Cytoadhesion assays were performed as follows: Target proteins (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) ,gg/ml, 0.1 ml/well) were immobilized onto plastic for 1 h at 370C. The plates were rinsed with serum-free media and nonspecific binding blocked by incubating 30 min at 370C with a solution of 10 mg/ml bovine skin gelatin (Sigma Chemical Co., St. Louis, MO). Cells were allowed to adhere to immobilized protein under serum-free conditions for 1 h at 370C. Nonadherent cells were removed by two gentle washes with warm (370C) serum-free medium. Adherent cells were then overlayered with semisolid media (methylcellulose or fibrinogen clot) containing, except where indicated, optimal concentrations of recombinant hematopoietic growth factors (1, 1 1). Controls consisted ofanalysis ofcellular attachment to both gelatin-coated wells and wells coated with thyroglobulin (Sigma Chemical Co.) as an inappropriate protein. Gelatin and thyroglobulin controls demonstrated an average of 12±1% progenitor cell binding (mean±SE, n = 7). However, this attachment was not significantly different from zero (P < 0.05). Nonetheless, the attachment to inappropriate protein (thyroglobulin) was subtracted from the total progenitor cell attachment. Thus, specific percent attachment for each lineage is defined as: [the total number of adherent progenitor cells (i.e., colonies) minus the number bound to the inappropriate immobilized protein (thyroglobulin) divided by the total number of input progenitor cells] times 100. The recombinant target proteins used in this study were expressed in yeast. Thrombospondin was purified from human platelets (1) and is a glycosylated protein. Recombinant interleukin-3 (IL-3) and granulocyte-macrophage colony-stimulating factor (GM-CSF) were purchased from Genzyme Corp., Boston, MA, and erythropoietin (Epo) from Amgen Biologicals, Thousand Oaks, CA.
Results and Discussion
In our experiments, we dissected the numerous hematopoietic regulatory interactions by utilizing recombinant cytokines, pure ECM molecules, and a purified population of human marrow cells that resembled hematopoietic stem cells. Such isolated marrow cell subpopulations are capable of not only multilineage differentiation, but also of self-renewal (12) (13) (14) (15) (16) (1, 19) , as do 10-40% of the progenitor cells that express HLA-DR (12) . A number of groups have shown that the acquisition of the DR' phenotype is a relatively late differentiation event, and that DR is expressed on more committed progenitor cells ( 12, 14) . Therefore (Fig. 2 A) . However, approximately four times as many erythroid precursors (BFU-E) adhere to erythropoietin than do CFU-GM. The HPP-CFC also adhere to erythropoietin, but to a lesser degree, perhaps indicating the multilineage potential of this cell (20) . By contrast, GM-CSF binds few erythroid and pluripotent progenitors but noticeably binds -15 times as many CFU-GM than it does BFU-E. Both IL-3 and the c-kit ligand also bind CD34' DR-CD15-progenitor cells and, again, specific attachment patterns are seen. Less than 15% of erythroid and pluripotent CD34+ DR-CD 15-progenitor cells attach to IL-3, in contrast to a 40-60% adherence for CFU-GM, HPP-CFC, and BFU-MK (Fig. 2 B) . Unlike IL-3, c-kit ligand binds relatively high numbers ofCD34+ DR-CD 1 5-erythroid and GEMM progenitor cells, and even higher percentages of BFU-MK and HPP-CFC.
Analysis ofCD34+ DR-CD 15-progenitor cell attachment data thus allows the definition ofa relative cytoadhesion phenotype (Table I) . It is interesting to note that the majority of primitive progenitors (HPP-CFC, BFU-MK, and CFU-GEMM) adhere to TSP, IL-3, and c-kit ligand, whereas the more committed progenitors (such as the CFU-GM) predominantly attach to IL-3 and GM-CSF. Most CD34+ DR-CD 15-erythroid progenitors adhere to TSP, with a lesser number also having the capacity to bind to erythropoietin or c-kit ligand. The BFU-MK adhere to TSP, IL-3, and c-kit ligand, and also attach to GM-CSF, but to a lesser degree. Finally, the majority of the CFU-GEMM show a restricted cytoadhesive pattern, attaching to TSP or c-kit ligand. Given the function of hematopoietic cytokines in mediating progenitor cell localization, we next examined whether the process ofcytoadhesion was sufficient to initiate cellular proliferation (as quantified by colony formation). In order to perform these studies, CD34+ DR-CD 15-cells were attached to immobilized proteins and subsequently cultivated without exogenous hematopoietic growth factors in the overlayer. (The maturation factor EPO was added to some cultures to permit development of BFU-E and CFU-GEMM colonies, see Fig. 1,   legend ). These studies demonstrate that hematopoietic progenitor cell attachment to extracellular matrix molecules (i.e., TSP and Fn), as well as to IL-3 and GM-CSF fails to stimulate proliferation (data not shown). Cytoadhesion of CD34+ DR-CD 15-progenitor cells to c-kit ligand, however, is sufficient to stimulate colony formation (Fig. 3 A) . Again, differential lineage effects are noted with few CFU-GM colonies, and no BFU-MK colonies developing under these conditions. Strikingly, equivalent numbers of BFU-E and HPP-CFU colonies develop when the sole stimulus is immobilized c-kit ligand. (Fig. 3 A) . This demonstrates that primitive megakaryocyte progenitor cells adhere to c-kit ligand, but the cytoadhesive event is insufficient (as a solitary stimulus) to initiate proliferation. In order to reconstitute a simplified hematopoietic microenvironment, we examined the interaction of CD34+ DR-CD 15-cells with a single hematopoietic growth factor in the presence ofa single ECM molecule. When TSP and c-kit ligand were admixed in equimolar concentrations and coimmobilized onto plastic, the observed colony formation was much greater than that predicted by the binding capacity of either molecule alone (Fig. 3 B) . This effect is particularly evident for CFU-GM and HPP-CFC, as it is to a lesser degree for CFU-GEMM and BFU-E. This suggests the existence of a subpopulation of CD34+ DR-CD 15-cells that adhere to either c-kit ligand or TSP, but fails to proliferate (or survive) in the absence ofbinding to the second ligand, even though adequate soluble growth factor is present to promote progenitor cell proliferation. Alternatively, TSP and c-kit ligand may form a protein-protein complex which "reconstitutes" a new or better cytoadhesive complex, thus binding more cells. In either case, it appears that a subpopulation of CD34+ DR-CD 15-progenitor cells exists that requires cooperative binding to both TSP and c-kit ligand to proliferate. Interestingly, primitive megakaryocyte precursors (BFU-MK) fail to respond to this simplified growth factor-ECM complex again, suggesting that other regulatory mechanisms may be operative in this lineage.
The observation of a synergistic cytoadhesive response to TSP and c-kit ligand, coupled with the actions of immobilized c-kit ligand as a hematopoietic growth factor, suggest that TSP and c-kit ligand together may constitute a growth-inductive signal. Neither TSP nor c-kit ligand function alone as CSFs for CD34+ DR-CD 15-progenitor cells. However, equimolar TSP and soluble c-kit ligand added directly to the fluid-phase of cultures function as a colony-stimulating activity (Fig. 4 A) . Importantly, -60% of the input BFU-E and > 80% of the input CFU-GEMM respond to this dual regulatory signal. TSP plus c-kit ligand also stimulates small numbers of CFU-GM and HPP-CFU. Again, the BFU-MK fail to respond to this combined matrix-cytokine signal, thus confirming the regulatory uniqueness ofthis lineage. In order to examine the specificity of the TSP-c-kit ligand interaction, TSP was cocultured with IL-3 (a powerful cytokine that drives the development of all lineages). In sharp contrast to the interaction between TSP and c-kit ligand, coculture ofTSP with IL-3 results in a diminution of IL-3 responsiveness (Fig. 4 B) . This inhibition suggests that in this context, TSP may down-modulate IL-3-promoted hematopoietic progenitor cell development. These data demonstrate both a role for TSP in modulating hematopoietic growth factor responsiveness and the uniqueness of the TSP-c-kit ligand interaction. Recently, a number of studies have identified the c-kit ligand as an important hematopoietic microenvironmental regulator (22) (23) (24) . The absence of or alterations in the c-kit ligand gene results in the microenvironmental defect associated with mutations at the steel locus. Furthermore, the c-kit ligand itself is a growth factor which augments primitive progenitor cell, mast cell, and committed progenitor cell development (22) (23) (24) . The c-kit ligand exists in both membrane-bound and soluble forms (25) . Functionally, its soluble form promotes progenitor cell development by synergistically modulating growth factor responsiveness, whereas the membrane-associated molecule directly stimulates cell proliferation and works as a ligand for cell-to-cell interactions (25, 26) . Our data demonstrates that soluble c-kit ligand, when immobilized, functions as a colonystimulating factor in the absence of other cytokines. Thus, changes occurring during the binding of c-kit ligand to plastic are sufficient to allow this cytokine to function as a CSF, perhaps mimicking the membrane-bound form of this molecule.
Information concerning interactions between primitive progenitor cells, matrix molecules, and hematopoietic growth factors is limited. Recent studies demonstrate that progenitor cell proliferation (in the presence of stromal cells) is associated with glycosaminoglycan-bound GM-CSF (6) , and that precise proteoglycanside chains (i.e., heparan sulfate) are responsible for binding both GM-CSF and IL-3 (5). These first reports of ECM growth factor interactions clearly demonstrate that matrix bound growth factor is presented in a biologically active form. Our observations demonstrated that another ECM growth factor "complex" (i.e., TSP and c-kit ligand) plays a role in hematopoietic stem cell development, and that the coimmobilization of these two proteins identifies a cell population of hematopoietic progenitor cells that requires adhesion to both ligands to undergo colony formation. Moreover, this ECM growth faction combination, when cocultured with CD34' DR-CD1 5-progenitor cells, functions as a colonystimulating activity for specific lineages of hematopoietic cells. These data thus represent the first report of a cytokine and ECM molecule functioning as a signal complex.
